{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:54Z","timestamp":1791252834684,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T00:00:00Z","timestamp":1406937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2015,2]]},"abstract":"Abstract<\/jats:title>\n \n Background & Aims<\/jats:title>\n \n Transarterial chemoembolization (\n TACE<\/jats:styled-content>\n ) is one of the standard treatments recommended for intermediate stage hepatocellular carcinoma (\n HCC<\/jats:styled-content>\n ). At the same time, only little is known about the use of radioembolization with Yttrium\u201090 microspheres (\n TARE<\/jats:styled-content>\n Y\u201090) for this subset of patients. To perform comparative analysis between both locoregional therapies in intermediate\n HCC<\/jats:styled-content>\n s. Primary endpoint was overall survival (\n OS<\/jats:styled-content>\n ), while safety, response rate and time\u2010to\u2010progression (\n TTP<\/jats:styled-content>\n ) were considered as secondary endpoints.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We collected data of 86\n HCC<\/jats:styled-content>\n patients in two university hospitals at which conventional\n TACE<\/jats:styled-content>\n with doxorubicin or\n TARE<\/jats:styled-content>\n Y\u201090 using glass microspheres were performed. The median observation period was 10\u00a0months. Patients were followed up for signs of toxicity and response. They underwent imaging analysis at baseline and follow\u2010up at regular time intervals.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Eighty\u2010six\n HCC<\/jats:styled-content>\n patients with intermediate stage B (\n BCLC<\/jats:styled-content>\n ) were treated with either\n TACE<\/jats:styled-content>\n (\n n<\/jats:italic>\n \u00a0=\u00a042) or\n TARE<\/jats:styled-content>\n Y\u201090 (\n n<\/jats:italic>\n \u00a0=\u00a044). Despite a higher tumour burden in the\n TARE<\/jats:styled-content>\n Y\u201090 group, the median\n OS<\/jats:styled-content>\n (\n TACE<\/jats:styled-content>\n : 18\u00a0months vs.\n TARE<\/jats:styled-content>\n Y\u201090: 16.4\u00a0months) and the median\n TTP<\/jats:styled-content>\n (\n TACE<\/jats:styled-content>\n : 6.8\u00a0months vs.\n TARE<\/jats:styled-content>\n Y\u201090: 13.3\u00a0months) were not statistically different. The number of treatment sessions, the average rate of treatment sessions per patient, total hospitalization time and rate of adverse events were significantly higher in the\n TACE<\/jats:styled-content>\n cohort.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n In intermediate\n HCC<\/jats:styled-content>\n stage patients, both treatments resulted in similar survival probabilities despite more advanced disease in the\n TARE<\/jats:styled-content>\n Y\u201090 group. Still,\n TARE<\/jats:styled-content>\n Y\u201090 was better tolerated and associated with less hospitalization and treatment sessions.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/liv.12637","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T04:43:12Z","timestamp":1404880992000},"page":"627-635","source":"Crossref","is-referenced-by-count":110,"title":["In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?"],"prefix":"10.1111","volume":"35","author":[{"given":"Amr","family":"El Fouly","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology University Hospital of Essen Essen Germany"},{"name":"Tropical Medicine Dep. Ain Shams University Hospital Cairo Egypt"},{"name":"Egyptian Atomic Energy Authority Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Ertle","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El Dorry","sequence":"additional","affiliation":[{"name":"Interventional Radiology Dep. Ain Shams University Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K.","family":"Shaker","sequence":"additional","affiliation":[{"name":"Tropical Medicine Dep. Ain Shams University Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dech\u00eane","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Abdella","sequence":"additional","affiliation":[{"name":"Tropical Medicine Dep. Ain Shams University Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mueller","sequence":"additional","affiliation":[{"name":"Institute for Nuclear Medicine University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Barakat","sequence":"additional","affiliation":[{"name":"Tropical Medicine Dep. Ain Shams University Hospital Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lauenstein","sequence":"additional","affiliation":[{"name":"Institute for Diagnostic and Interventional Radiology and Neuroradiology University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bockisch","sequence":"additional","affiliation":[{"name":"Institute for Nuclear Medicine University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg F.","family":"Schlaak","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology University Hospital of Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.18.1983"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn134"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.12.015"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.032"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.008"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2006.06.016"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3282fc2633"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20526"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.6004\/jnccn.2009.0027","article-title":"NCCN clinical practice guidelines in oncology: hepatobiliary cancers","volume":"4","author":"Benson AB","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq166"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23944"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24451"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.049"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f10f04"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000233785.75257.9A"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058347"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.10.004"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33156"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08649-X"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20036"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013569329846"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.006"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.028"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104"},{"key":"e_1_2_6_31_1","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"4","author":"Bolondi L","year":"2012","journal-title":"Semin Liver Dis"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20636"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24030"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02695.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_6_37_1","first-page":"1539","article-title":"The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE)","volume":"91","author":"Leelawat K","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.06.017"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-005-0171-4"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12637","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:46:01Z","timestamp":1695548761000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/liv.12637"],"URL":"https:\/\/doi.org\/10.1111\/liv.12637","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,2]]}}}